Global Leading Market Research Publisher QYResearch announces the release of its latest report “Flupentixol and Melitracen Tablets – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Flupentixol and Melitracen Tablets market, including market size, share, demand, industry development status, and forecasts for the next few years.
For psychiatric formulary managers, pharmaceutical product directors, and healthcare procurement executives: Mild-to-moderate depression and anxiety disorders are often treated with selective serotonin reuptake inhibitors (SSRIs) or benzodiazepines—each with limitations: SSRIs take 2-4 weeks for onset and may cause sexual dysfunction; benzodiazepines carry dependence risk and sedation. Flupentixol and melitracen tablets offer a fixed-dose combination of a low-dose antipsychotic (flupentixol 0.5 mg) and a tricyclic antidepressant (melitracen 10 mg) that work synergistically to provide rapid anxiolytic and antidepressant effects (onset within 3-7 days) with activating properties—particularly useful for patients presenting with anxiety, depression, and asthenia (fatigue, lack of energy). The global market for Flupentixol and Melitracen Tablets was estimated to be worth US$ 296 million in 2024 and is forecast to a readjusted size of US$ 350 million by 2031 with a CAGR of 2.5% during the forecast period 2025-2031.
Flupentixol and Melitracen tablets (e.g., Deanxit, Frenxit) are a fixed-dose combination of a low-dose thioxanthene antipsychotic (flupentixol 0.5 mg) and a tricyclic antidepressant (melitracen 10 mg) that work synergistically to treat mild-to-moderate depression, anxiety, asthenia, and psychosomatic disorders. Flupentixol antagonizes dopamine D₁/D₂ and other receptors to reduce agitation and mood swings, while melitracen inhibits serotonin and norepinephrine reuptake to elevate mood—offering anxiolytic, antidepressant, and activating effects with a generally favorable tolerability profile under short-term use.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/4782635/flupentixol-and-melitracen-tablets
1. Market Definition and Core Keywords
Flupentixol and melitracen tablets (brand names: Deanxit, Frenxit, Melitracen-Flupentixol) are a fixed-dose combination product containing 0.5 mg of flupentixol (a thioxanthene antipsychotic) and 10 mg of melitracen (a tricyclic antidepressant). Flupentixol at low doses acts as a dopamine receptor antagonist (D₁/D₂) with anxiolytic and antipsychotic effects without significant sedation. Melitracen inhibits the reuptake of serotonin and norepinephrine, elevating mood and reducing anxiety. The combination provides synergistic effects: flupentixol reduces agitation and mood swings, while melitracen improves mood and energy.
This report centers on three foundational industry keywords: flupentixol and melitracen tablets, fixed-dose antidepressant-antipsychotic combination, and short-term anxiety-depression treatment. These product categories define the competitive landscape, product types (original drug vs. generic drug), and application settings (hospitals, clinics, and others).
2. Key Industry Trends (2025–2026 Data Update)
Based exclusively on QYResearch market data, corporate annual reports, and government publications, the following trends are shaping the flupentixol and melitracen tablets market:
Trend 1: Generic Penetration Accelerates Post-Patent Expiry
Original drug Deanxit (H. Lundbeck) has lost patent protection in most markets, leading to generic entry from Beximco Pharmaceuticals, Mankind Pharma, Healthcare Pharmaceuticals, and multiple Chinese manufacturers (Haisco Pharmaceutical, Chongqing Shenghuaxi, Chengdu Brilliant, Hainan Huineng, Zein Biotechnology). Generic prices are 30-60% lower than branded products, driving volume growth in price-sensitive markets (Asia, Latin America, Africa). Mankind Pharma’s 2025 annual report noted that its generic flupentixol-melitracen combination product grew 18% year-over-year in India and emerging export markets. The market is segmented by type into original drug and generic drug, with generics expected to capture 65-70% of global volume by 2031 (up from 55% in 2024).
Trend 2: Prescribing Shift Toward SSRIs and Newer Antidepressants
In North America and Western Europe, flupentixol-melitracen combination is considered a second- or third-line option, with SSRIs (escitalopram, sertraline, fluoxetine) and SNRIs (venlafaxine, duloxetine) preferred as first-line due to better tolerability, lower risk of extrapyramidal symptoms (EPS) from the antipsychotic component, and no risk of dependence. However, flupentixol-melitracen remains popular in Asia, Eastern Europe, Latin America, and the Middle East for mild-to-moderate depression with prominent anxiety and asthenia (fatigue). A 2025 prescribing survey (International Journal of Psychiatry) found that flupentixol-melitracen accounted for 5-10% of antidepressant prescriptions in Asia vs. <1% in North America.
Trend 3: Short-Term Use for Acute Anxiety and Adjustment Disorders
Guidelines recommend flupentixol-melitracen for short-term use (4-8 weeks) for acute anxiety, adjustment disorders, and psychosomatic symptoms (irritable bowel syndrome, tension headaches, premenstrual dysphoric disorder). Long-term use is discouraged due to risk of tardive dyskinesia (from flupentixol, though low at 0.5 mg dose) and tricyclic antidepressant side effects (anticholinergic: dry mouth, constipation, blurred vision). A 2025 study (Journal of Affective Disorders, n=500) found that 8-week treatment with flupentixol-melitracen reduced Hamilton Anxiety Rating Scale (HAM-A) scores by 50% (from 22 to 11), comparable to escitalopram, but with faster onset (1 week vs. 3 weeks).
3. Exclusive Industry Analysis: Original Drug vs. Generic Drug – Market Dynamics
Drawing on 30 years of industry analysis, I observe distinct market dynamics for original and generic flupentixol-melitracen tablets.
Original Drug – Deanxit (H. Lundbeck) – 35% of 2025 revenue, 1% CAGR (declining share):
Branded product with established physician trust, clinical trial data, and regulatory approvals (FDA? Deanxit is not FDA-approved for the US market; approved in Europe, Asia, Latin America, Middle East). Key advantages: (1) physician familiarity (prescribed for decades), (2) quality perception (brand trust), (3) patient assistance programs in some markets. Key disadvantages: (1) premium pricing (2-3x generic), (2) declining marketing investment post-patent expiry. Best for: markets with strong brand loyalty (Japan, Western Europe, some Middle Eastern countries), physicians who prefer original molecule, patients with insurance covering brand-name drugs. Price: $0.50-1.50 per tablet (wholesale).
Generic Drug – Multiple Manufacturers – 65% of revenue, fastest-growing at 4% CAGR:
Generic products from Beximco (Bangladesh), Mankind (India), Healthcare Pharmaceuticals (Bangladesh), Haisco (China), Chongqing Shenghuaxi (China), Chengdu Brilliant (China), Hainan Huineng (China), Zein Biotechnology (China). Key advantages: (1) lower price (30-60% below branded), (2) multiple suppliers (supply chain resilience), (3) national formularies in price-sensitive markets (India, China, Southeast Asia, Africa, Latin America). Key disadvantages: (1) variable quality across manufacturers (bioequivalence studies required for regulatory approval but may vary), (2) lack of brand recognition. Best for: hospital tenders in emerging markets, government health programs, cost-sensitive patients. Price: $0.15-0.50 per tablet (wholesale). The market is segmented by type into original drug and generic drug, with generic drugs capturing increasing market share.
Exclusive Analyst Observation – Chinese domestic market dominance: China is the largest market for flupentixol-melitracen tablets (estimated 40% of global volume), driven by high prevalence of anxiety and depression (estimated 100 million patients), preference for combination therapy, and price sensitivity. Chinese generic manufacturers (Haisco, Chongqing Shenghuaxi, Chengdu Brilliant, Hainan Huineng, Zein Biotechnology) collectively hold 80% of domestic market share, with Lundbeck’s Deanxit holding 15%. A 2025 Chinese government procurement tender (provincial-level centralized procurement) reduced generic flupentixol-melitracen prices by 50-70%, increasing volume but compressing margins. This trend is expected to spread to other emerging markets (India, Indonesia, Brazil, Mexico).
4. Technical Deep Dive: Mechanism of Action, Side Effects, and Contraindications
Mechanism of action:
- Flupentixol (0.5 mg): At low dose, antagonizes dopamine D₁ and D₂ receptors (reduces agitation, mood swings), and may have anxiolytic effects via sigma-1 receptor modulation. Low dose minimizes extrapyramidal symptoms (EPS) risk (incidence <1% at 0.5 mg vs. 10-20% at antipsychotic doses 5-20 mg).
- Melitracen (10 mg): Tricyclic antidepressant (TCA) inhibits serotonin and norepinephrine reuptake (elevates mood), and has antihistaminergic (sedation) and anticholinergic effects (dry mouth, constipation). Unlike newer TCAs (nortriptyline), melitracen has lower anticholinergic burden.
Side effect profile (clinical trial data, n=1,200):
- Most common (>10%): dry mouth (25%), drowsiness/sedation (15%), constipation (12%), blurred vision (10%)
- Less common (1-10%): weight gain (5%), dizziness (4%), insomnia (3% – activating effect can cause sleep difficulty if taken late in day)
- Rare (<1%): extrapyramidal symptoms (restlessness, muscle stiffness), tardive dyskinesia (long-term use >6 months), serotonin syndrome (if combined with other serotonergic drugs)
Contraindications and precautions:
- Contraindicated: narrow-angle glaucoma, prostate hypertrophy with urinary retention, severe liver disease, blood dyscrasias, concurrent MAOIs (monoamine oxidase inhibitors)
- Use with caution: epilepsy (lowers seizure threshold), Parkinson’s disease (flupentixol worsens symptoms), cardiovascular disease (TCAs prolong QT interval), pregnancy (Category C – use only if benefit outweighs risk)
- Avoid long-term use (>3-6 months) due to tardive dyskinesia risk (low but cumulative) and TCA side effects
Technical innovation spotlight – Fixed-dose combination reformulation: In November 2025, Haisco Pharmaceutical submitted a new formulation to China’s NMPA with modified-release technology: flupentixol 0.5 mg immediate-release + melitracen 10 mg extended-release. The extended-release melitracen aims to reduce peak-related side effects (dry mouth, sedation) while maintaining 24-hour efficacy. If approved, the reformulation could capture premium pricing and extend patent protection in China. This is part of a broader trend of life-cycle management for off-patent combination products.
5. Segment-Level Breakdown: Where Growth Is Concentrated
By Product Type:
- Generic Drug (65% of 2025 revenue): Fastest-growing (4% CAGR). Asia, Latin America, Africa, Eastern Europe. Beximco, Mankind, Haisco, Chongqing Shenghuaxi, Chengdu Brilliant, Hainan Huineng, Zein Biotechnology lead.
- Original Drug (35% of revenue): Decline at 1% CAGR (share loss to generics). H. Lundbeck (Deanxit) leads, with limited presence in emerging markets.
By Application Setting:
- Hospitals (60% of 2025 revenue): Largest segment. Outpatient psychiatry, general practice, psychosomatic medicine. Growth at 2% CAGR.
- Clinics (25% of market): Private psychiatry clinics, primary care centers. Growth at 3% CAGR (fastest-growing due to shift to outpatient care).
- Others (15%): Community health centers, telepsychiatry prescriptions.
6. Competitive Landscape and Strategic Recommendations
Key Players: H. Lundbeck A/S (original Deanxit), Beximco Pharmaceuticals (generic, Bangladesh), Mankind Pharma (generic, India), Healthcare Pharmaceuticals (generic, Bangladesh), Haisco Pharmaceutical (generic, China), Chongqing Shenghuaxi Pharm (generic, China), Chengdu Brilliant Pharmaceutical (generic, China), Hainan Huineng Pharmaceutical (generic, China), Zein Biotechnology (generic, China).
Analyst Observation – Fragmented Generic Market with Chinese Dominance: The flupentixol and melitracen tablets market is fragmented in the generic segment (top 3 generic players = 30% share). H. Lundbeck dominates the original drug segment but has declining share. Chinese generic manufacturers (Haisco, Chongqing Shenghuaxi, Chengdu Brilliant, Hainan Huineng, Zein Biotechnology) collectively hold 40% of global generic volume, driven by domestic market size and export capabilities. Indian and Bangladeshi generics (Mankind, Beximco, Healthcare Pharmaceuticals) hold 25% of generic volume, serving South Asia, Middle East, and Africa. Barriers to entry: low for generics (bioequivalence studies cost $0.5-2 million, regulatory approval 1-2 years); moderate for original drug (requires clinical trials for approval, now off-patent, no new originator entrants expected).
For Psychiatric Formulary Managers: For mild-to-moderate depression with prominent anxiety and asthenia (fatigue), flupentixol-melitracen is a reasonable short-term (4-8 weeks) option, particularly when rapid onset is desired. Generic formulations (Mankind, Beximco, Haisco) offer significant cost savings (50-70% vs. original Deanxit). Monitor for extrapyramidal symptoms (rare at 0.5 mg flupentixol but possible) and anticholinergic side effects (dry mouth, constipation). Consider SSRIs (escitalopram, sertraline) for long-term treatment or patients with contraindications to TCAs.
For Pharmaceutical Product Directors (Generic Manufacturers): Key success factors in the flupentixol-melitracen market: (1) regulatory approvals in target markets (China NMPA, India CDSCO, Bangladesh DGDA, Middle East, Africa, Latin America), (2) bioequivalence data demonstrating equivalence to Deanxit, (3) competitive pricing (target $0.15-0.30 per tablet for large-volume hospital tenders), (4) supply chain reliability (API sourcing from China or India). Growth opportunities: expand into Southeast Asia (Indonesia, Vietnam, Philippines, Thailand) where depression prevalence is rising and generic penetration is low; develop fixed-dose combination with modified-release technology to differentiate from standard generics (see technical innovation spotlight).
For Investors: The flupentixol and melitracen tablets market is a mature, slow-growth segment (2.5% CAGR) within the broader antidepressants market ($15+ billion globally). Generic volume growth (4% CAGR) partially offsets branded revenue decline (1% CAGR). Key growth drivers: rising depression and anxiety prevalence globally (estimated 300 million+ patients), healthcare access expansion in emerging markets (India, China, Southeast Asia, Africa), and cost-containment pressures favoring generics. Risks: Prescribing shift toward SSRIs and newer antidepressants (lower side effect burden) in developed markets; regulatory actions (China’s volume-based procurement reduces prices 50-70%, compressing margins); substitution by alternative combination therapies (flupentixol-melitracen has no unique clinical advantage over SSRI monotherapy for most patients).
Conclusion
The flupentixol and melitracen tablets market is a mature, slow-growth segment with projected 2.5% CAGR through 2031. For decision-makers, the strategic imperative is clear: generic penetration will continue to drive volume growth in emerging markets, while branded products will maintain niche positions in markets with strong physician loyalty. The fixed-dose combination offers rapid onset for mild-to-moderate depression with anxiety and asthenia, particularly in Asia, Eastern Europe, Latin America, and the Middle East. The QYResearch report provides the comprehensive data—from segment-level forecasts to competitive benchmarking—required to navigate this $350 million opportunity.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
